Please login to the form below

Not currently logged in
Email:
Password:

Adaptimmune appoints former GSK executives

Dr Rafael Amado and Adrian Rawcliffe join the biotech’s top ranks

Rafael AmadoAdaptimmune has strengthened its senior management team with the appointment of Dr Rafael Amado, as its new chief medical officer, and Adrian Rawcliffe, as its chief financial officer.

The appointments are effective from 16 March and will see Dr Amado lead Adaptimmune's clinical strategy and assume responsibility for the company's clinical trials across the US and Europe under its strategic collaboration with GlaxoSmithKline.

He will also lead the development of the company's pipeline of research programmes.

Adrian RawcliffePrior to joining Adaptimmune, Dr Amado served as senior VP and head of oncology R&D at GSK, where he was responsible for integrating oncology global R&D activities, from drug target identification to clinical development and registration.

Dr Amado said: “I am pleased to be joining Adaptimmune at this exciting time. I have been impressed by the quality of the science and look forward to working with the team as we seek to bring potential breakthrough cancer therapies to patients.”

Meanwhile Rawcliffe will lead Adaptimmune's financial management and operations functions including compliance and risk management.

He also joins from GSK where he was senior VP of finance at its North American pharmaceuticals business.

James Noble, chief executive Officer of Adaptimmune, said: “I am delighted that Rafael and Ad are joining the company. Each brings a wealth of invaluable experience to complement the expertise of our existing senior management team.”

5th March 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics